Minneslate Logo

HF1271 (Legislative Session 94 (2025-2026))

Provisions regarding the sale of cannabinoids derived from hemp modified, person selling edible cannabinoids permitted to convert the person's registration to a comparable hemp license, and hemp-derived topical product provisions modified.

Related bill: SF1729

AI Generated Summary

This Minnesota House bill (H.F. No. 1271) seeks to modify existing laws regarding the sale and regulation of hemp-derived cannabinoid products. Key provisions include:

  1. Regulation of Cannabinoid Sales:

    • Non-intoxicating cannabinoids, including edible products, can be sold for human or animal consumption if they meet legal requirements.
    • Products must not contain more than 0.3% tetrahydrocannabinol (THC), and edible products must adhere to established THC limits.
    • Non-edible cannabinoid-containing products must be for external use only and cannot be consumed through inhalation, ingestion, or injection.
    • Cannabinoids cannot be marketed for treating diseases or affecting bodily functions.

  2. Age Restriction:

    • No cannabinoid or THC-containing products may be sold to individuals under 21.

  3. Onsite Consumption Rules:

    • Products can be sold for onsite consumption if the retailer also holds a liquor license.
    • Products must remain in their original packaging except for statutory exceptions.
    • Consumers cannot mix cannabinoid products with alcohol or take removed packaging off-premises.

  4. Hemp Edible Manufacturing Standards:

    • Manufacturers must comply with state and local building, fire, and zoning regulations.
    • Licensed premises must be kept clean and free of infestation.

  5. Labeling Requirements for Hemp-Derived Topical Products:

    • Packages must include details such as the manufacturer’s information, lab testing details, product weight, cannabinoid content, ingredient list, and disclaimers.
    • Certain information may be provided via a scannable barcode linking to a website.

  6. Prohibitions on Sale and Manufacturing:

    • Products cannot be marketed or used for disease treatment.
    • Inhalable, chewable, injectable, or improperly diluted products are prohibited.
    • Products must not contain harmful additives, contaminants, or incorrect cannabinoid amounts.

Overall, this bill aims to enhance consumer protections, clarify licensing requirements, and ensure the safe sale and labeling of hemp-derived cannabinoids in Minnesota.

Bill text versions

Actions

DateChamberWhereTypeNameCommittee Name
February 20, 2025HouseActionIntroduction and first reading, referred toCommerce Finance and Policy
April 01, 2025HouseActionAuthor added

Citations

 
[
  {
    "analysis": {
      "added": [
        "Clarifies external application rules, label information requirements, and conditions for on-site consumption."
      ],
      "removed": [
        "Previously allowed broader conditions for cannabinoid product sales."
      ],
      "summary": "This bill amends the sale rules for cannabinoids derived from hemp under section 151.72, subdivision 3, establishing specific conditions under which these products may be sold.",
      "modified": [
        "Adjusts THC content limits and further restricts underage sales."
      ]
    },
    "citation": "151.72 subdivision 3"
  },
  {
    "analysis": {
      "added": [
        "Legal distinction for compliant hemp-derived cannabinoid products."
      ],
      "removed": [],
      "summary": "Explains that products conforming to the new cannabinoid regulations will not be considered controlled substances under section 152.02.",
      "modified": [
        "Clarifies the legal status of compliant products as non-controlled substances."
      ]
    },
    "citation": "152.02"
  },
  {
    "analysis": {
      "added": [
        "New requirements for hemp edible manufacturers regarding building and sanitary conditions."
      ],
      "removed": [],
      "summary": "This bill adds a subdivision to section 342.45 to mandate compliance with building regulations for hemp edible manufacturers.",
      "modified": []
    },
    "citation": "342.45"
  },
  {
    "analysis": {
      "added": [
        "Includes specific information that must be included on product labels such as manufacturer details and disclaimers."
      ],
      "removed": [],
      "summary": "Amends labeling requirements for hemp-derived topical products under section 342.63, subdivision 5.",
      "modified": [
        "Updates format and methods for providing product information, including digital options."
      ]
    },
    "citation": "342.63 subdivision 5"
  },
  {
    "analysis": {
      "added": [
        "Specifies unacceptable conditions for cannabinoid products in terms of safety and labeling."
      ],
      "removed": [],
      "summary": "Updates prohibitions on the sale of cannabinoid products in section 342.66, subdivision 6.",
      "modified": [
        "Clarifies restrictions on product composition and contaminants."
      ]
    },
    "citation": "342.66 subdivision 6"
  }
]

Progress through the legislative process

17%
In Committee

Sponsors